Arylsulfatase H inhibitors would constitute a group of chemical compounds designed to selectively inhibit the activity of arylsulfatase H (ARSH), an enzyme that is part of the sulfatase family. These enzymes are known to hydrolyze sulfate esters, a crucial step in the metabolism of sulfate conjugates, including glycosaminoglycans, steroids, and other molecules that contain sulfate groups. The specific biochemical role of ARSH within this family might involve the cleavage of sulfate groups from a variety of substrates, contributing to the regulation of sulfate homeostasis within the body. Inhibitors of ARSH would be expected to interact with the active site of the enzyme or with regions critical for its stability or substrate recognition, thereby impeding its sulfatase activity. The development of such inhibitors would likely be predicated on a detailed understanding of the enzyme's structure, gained through high-resolution imaging techniques, which would facilitate the identification of potential binding pockets or allosteric sites amenable to small-molecule intervention.
The journey toward creating ARSH inhibitors would begin with the identification of potential lead compounds, often through high-throughput screening of diverse chemical libraries for molecules that demonstrate an ability to bind to the enzyme and inhibit its activity. Initial hits would undergo a battery of biochemical assays designed to quantify their potency and specificity in inhibiting ARSH. These assays could involve measuring the enzyme's activity in the presence of various potential inhibitors using colorimetric or fluorometric substrates whose cleavage is indicative of sulfatase activity. Promising compounds would then be advanced to the lead optimization phase, where they would be systematically modified in an effort to enhance their potency, selectivity, and pharmacokinetic properties. This stage would incorporate the principles of medicinal chemistry and structure-activity relationships (SAR), as well as computational modeling and molecular dynamics simulations to predict how changes in chemical structure might affect the interaction with ARSH and the resulting inhibitory effect.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Sodium chlorate | 7775-09-9 | sc-212938 | 100 g | $58.00 | 1 | |
It is known to inhibit sulfatase activity by oxidizing the critical active site cysteine residue to cysteic acid, potentially affecting ARSH activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
It can raise the pH of acidic vesicles, potentially affecting the maturation and function of lysosomal enzymes, including sulfatases. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
As a folate analogue, it can affect cell proliferation and may indirectly reduce the expression of various enzymes, potentially including ARSH. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits eukaryotic protein synthesis by interfering with ribosome function, which could reduce ARSH protein levels. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts the Golgi apparatus and protein trafficking, which might affect the processing and function of ARSH as a lysosomal enzyme. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibits N-linked glycosylation, which is essential for the proper folding and function of many enzymes, potentially including ARSH. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can lead to the accumulation of misfolded proteins, possibly affecting ARSH levels and activity. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $275.00 $928.00 $1543.00 | 14 | |
An irreversible cysteine protease inhibitor that could affect lysosomal function and indirectly impact ARSH activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Affects gene expression and cell differentiation, which may indirectly alter the expression levels of certain enzymes, including ARSH. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
As a steroid hormone, it can modulate gene expression and could have effects on the expression of enzymes like ARSH. |